Free shipping on orders over $150
R E T A 40mg research vial

peptides

R E T A 40mg

R E T A is a GLP-3 class research peptide investigated in laboratory models for incretin-pathway signaling, energy expenditure, and body-composition endpoints. Supplied lyophilized at 99%+ HPLC purity.

Research-observed benefits

  • GLP-3 class incretin signaling
  • Body-composition endpoints
  • Energy-expenditure research
  • Glycemic-marker models

Findings reported in in-vitro / preclinical research literature. Not therapeutic claims.

CAS Number

Purity

99%+

Molecular Formula

Stock

500 units

Order type

Purchase option

Quantity

1

Total

$110

For in-vitro research only. Not for human consumption, diagnostic, or therapeutic use. Storage at -20°C recommended for lyophilized peptides.

R E T A 40mg — Full Research Breakdown

Tailored information for researchers. All content is for in-vitro / preclinical research context only — not medical advice.

Mechanism of Action

GLP-3 class multi-receptor incretin agonist. Engages incretin and glucagon-family receptors simultaneously, combining satiety and insulinotropic signaling with increased energy expenditure in laboratory models.

How It Helps

The multi-receptor profile is why researchers use it to model body-composition and metabolic-rate endpoints that single-receptor agonists do not reproduce.

Half-Life

Long-acting; supports weekly intervals in study designs

Onset of Effects

Metabolic-marker shifts commonly observed within 2–4 weeks in model systems.

Storage

Lyophilized: –20°C. Reconstituted: 2–8°C, 28 days. Protect from light.

Stacks Well With

  • Cagrilintide (amylin satiety pathway)
  • Tesamorelin (body composition)

Research-Observed Side Effects

  • Nausea
  • Reduced appetite
  • Transient GI discomfort
  • Injection-site reaction

Translational Cautions

  • Gastroparesis models
  • Prior sensitivity to incretin analogs

Research Highlights

  • Multi-receptor agonism produces larger composition changes than single-pathway comparators in published models.
  • Glucagon-receptor engagement is associated with increased energy expenditure alongside appetite suppression.
  • Titration-style designs are used to characterize tolerability across concentrations.

Researcher FAQ